diaMentis

Mental health disorders affect 1 in 8 people worldwide, yet psychiatry still lacks objective diagnostic tools. In 2020, driven by the COVID-19 pandemic, rates of anxiety and depression soared by over 25%. At the same time, suicide remains the third leading cause of death among 15 to 29-year-olds—90% of those deaths linked to untreated mental illness.

The economic cost is staggering: $5 trillion per year in lost productivity and care. But the human cost is immeasurable. With current methods relying solely on clinical observation and patient-reported symptoms, many people face delays as long as 11 years between first symptoms. 

diaMentis is pioneering a revolutionary diagnostic solution for mental health, based on retinal signal analysis—offering a sharp contrast to traditional, subjective methods. Their disruptive approach includes:

• A non-invasive retinal signal exam that collects objective biomarkers.
• Advanced AI algorithms that decipher the retinal signal and deliver mental health insights in under 24 hours.
• A software anatomical device and a dedicated hardware solution in development.
• Clinical validation showing over 98% accuracy in detection and prediction. A diagnostic support tool designed to assist clinicians in both diagnosis and therapeutic decisions.

By moving psychiatry into the era of precision medicine, diaMentis stands out in a field dominated by trial-and-error approaches.

diaMentis is transforming mental health through technological innovation, driving measurable social progress as:

• Enable early diagnosis and timely care, improving quality of life.
• Reduce misdiagnosis and ineffective treatments.
• Offer potential suicide prevention through early detection.

To support and scale its innovation, diaMentis plans to leverage the 3DEXPERIENCE platform to accelerate development and clinical integration with these solutions:

• CATIA: For 3D modeling and systems engineering of the diagnostic device.
• BIOVIA: For electronic Quality Management Systems (eQMS).
• MEDIDATA: For clinical trial data management and regulatory compliance.
• ENOVIA: For end-to-end program management and collaboration.

At the heart of diaMentis’s success lies a strong leadership network and a collaborative mindset. They have built a powerful ecosystem of experts, clinicians, and partners, and their partnership with Dassault Systèmes exemplifies their belief in collective intelligence.

Together, they are working toward a common vision: to transform brain health diagnostics, improve lives, and create long-term value for both patients and healthcare systems.